The present invention discloses a compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof wherein n represents 0 to 2 A represents an arylene group or a heteroarylene group G represents a single bond, an oxygen atom or CH2 E represents a nitrogen-containing non-aromatic heterocycle R1 represents an alkoxy group, an alkoxy alkoxy group or the like R2 represents a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, a hydroxy alkyl group, a nitrogen-containing non-aromatic heterocyclic group or the like R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like and R4 represents a C1-6 alkyl group, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom. The compound of formula (IA) or a pharmaceutically acceptable salt thereof has an FGFR1 inhibitory action, an FGFR2 inhibitory action and an action to selectively inhibit an FGF/FGFR signal against a VEGF/KDR signal, particularly, a selective FGFR1, FGFR2 or FGFR3 inhibitory action. The compound of formula (IA) of the present invention or a pharmaceutically acceptable salt thereof has a potential use for a therapeutic agent for stomach cancer, non-small-cell lung carcinoma including lung squamous cell carcinoma, bladder cancer or endometrial cancer.
